126 related articles for article (PubMed ID: 38063319)
1. Design, Synthesis, and Bioactivity Evaluations of 3-Methylenechroman-2-one Derivatives as Thioredoxin Reductase (TrxR) Inhibitors.
Nikitjuka A; Ozola M; Krims-Davis K; Žalubovskis R
ChemMedChem; 2024 Feb; 19(3):e202300504. PubMed ID: 38063319
[TBL] [Abstract][Full Text] [Related]
2. Exploration of 3,4-unsubstituted coumarins as thioredoxin reductase 1 inhibitors for cancer therapy.
Nikitjuka A; Ozola M; Jackevica L; Bobrovs R; Žalubovskis R
Org Biomol Chem; 2023 Dec; 21(48):9630-9639. PubMed ID: 38018884
[TBL] [Abstract][Full Text] [Related]
3. May 1,2-Dithiolane-4-carboxylic Acid and Its Derivatives Serve as a Specific Thioredoxin Reductase 1 Inhibitor?
Nikitjuka A; Krims-Davis K; Kaņepe-Lapsa I; Ozola M; Žalubovskis R
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764424
[TBL] [Abstract][Full Text] [Related]
4. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity.
Gan FF; Kaminska KK; Yang H; Liew CY; Leow PC; So CL; Tu LN; Roy A; Yap CW; Kang TS; Chui WK; Chew EH
Antioxid Redox Signal; 2013 Oct; 19(11):1149-65. PubMed ID: 23311917
[TBL] [Abstract][Full Text] [Related]
5. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
[TBL] [Abstract][Full Text] [Related]
6. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of benzylidenecyclohexenones as TrxR inhibitors displaying high anticancer activity and inducing ROS, apoptosis, and autophagy.
Qian J; Xu Z; Meng C; Liu J; Hsu PL; Li Y; Zhu W; Yang Y; Morris-Natschke SL; Lee KH; Zhang Y; Ling Y
Eur J Med Chem; 2020 Oct; 204():112610. PubMed ID: 32736231
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor.
Fan QZ; Zhou J; Zhu YB; He LJ; Miao DD; Zhang SP; Liu XP; Zhang C
Bioorg Chem; 2020 Dec; 105():104401. PubMed ID: 33113415
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
10. Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl
Truong D; Sullivan MP; Tong KKH; Steel TR; Prause A; Lovett JH; Andersen JW; Jamieson SMF; Harris HH; Ott I; Weekley CM; Hummitzsch K; Söhnel T; Hanif M; Metzler-Nolte N; Goldstone DC; Hartinger CG
Inorg Chem; 2020 Mar; 59(5):3281-3289. PubMed ID: 32073260
[TBL] [Abstract][Full Text] [Related]
11. Thimerosal, a competitive thioredoxin reductase 1 (TrxR1) inhibitor discovered via high-throughput screening.
Ni Y; Luo Z; Lv Y; Ma S; Luo C; Du D
Biochem Biophys Res Commun; 2023 Apr; 650():117-122. PubMed ID: 36780763
[TBL] [Abstract][Full Text] [Related]
12. Thioredoxin reductase inhibitors: a patent review.
Zhang B; Zhang J; Peng S; Liu R; Li X; Hou Y; Han X; Fang J
Expert Opin Ther Pat; 2017 May; 27(5):547-556. PubMed ID: 27977313
[TBL] [Abstract][Full Text] [Related]
13. Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads.
Kaminska KK; Bertrand HC; Tajima H; Stafford WC; Cheng Q; Chen W; Wells G; Arner ES; Chew EH
Oncotarget; 2016 Jun; 7(26):40233-40251. PubMed ID: 27244886
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
15. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.
Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
J Biol Chem; 2006 Apr; 281(16):10691-7. PubMed ID: 16481328
[TBL] [Abstract][Full Text] [Related]
16. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.
Wang L; Yang Z; Fu J; Yin H; Xiong K; Tan Q; Jin H; Li J; Wang T; Tang W; Yin J; Cai G; Liu M; Kehr S; Becker K; Zeng H
Free Radic Biol Med; 2012 Mar; 52(5):898-908. PubMed ID: 22210352
[TBL] [Abstract][Full Text] [Related]
17. Acetaminophen reactive intermediates target hepatic thioredoxin reductase.
Jan YH; Heck DE; Dragomir AC; Gardner CR; Laskin DL; Laskin JD
Chem Res Toxicol; 2014 May; 27(5):882-94. PubMed ID: 24661219
[TBL] [Abstract][Full Text] [Related]
18. Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.
Jovanović M; Zhukovsky D; Podolski-Renić A; Domračeva I; Žalubovskis R; Senćanski M; Glišić S; Sharoyko V; Tennikova T; Dar'in D; Pešić M; Krasavin M
Eur J Med Chem; 2019 Nov; 181():111580. PubMed ID: 31400708
[TBL] [Abstract][Full Text] [Related]
19. Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
Yan J; Xu Y; Jin X; Zhang Q; Ouyang F; Han L; Zhan M; Li X; Liang B; Huang X
Eur J Med Chem; 2022 Jan; 227():113897. PubMed ID: 34649064
[TBL] [Abstract][Full Text] [Related]
20. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
